New cancer drug CFI-402257 enters first human trial
NCT ID NCT02792465
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It was the first time this drug was given to humans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CFI-402257
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial, so the drug may not be effective or could have unexpected side effects. It is the first time CFI-402257 is tested in humans, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada